Board at its meeting held today interalia approved Unaudited Financial Results (both standalone and consolidated) for the quarter and nine months ended 31.12.2025 of FY 2025-26
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sunil Healthcare's board approved unaudited Q3 and nine-month FY26 results on 6 February 2026, reviewed by Singhi & Co. with an unmodified limited review report. On a standalone basis, Q3 revenue from operations was about Rs. 2,352 lakhs versus Rs. 2,046 lakhs in Q3 FY25, while nine-month standalone revenue rose modestly to about Rs. 6,800 lakhs. Consolidated nine-month revenue was approximately Rs. 8,476 lakhs (vs Rs. 7,909 lakhs last year) and consolidated profit after tax jumped to about Rs. 635 lakhs from Rs. 490 lakhs, a roughly 30% year-on-year increase. Consolidated results include two foreign subsidiaries — Sunil Healthcare Mexico SA De CV and Sunil Healthcare North America LLC — which together contributed negligible revenue but around Rs. 97 lakhs of net profit for the nine-month period.
Shareholders should note the standout is the consolidated bottom line, up nearly 30% YoY for 9M FY26 on a higher revenue base, likely aided by overseas subsidiaries. Standalone earnings are broadly flat, so the consolidated growth story depends on subsidiary performance — worth watching for sustainability.